Centessa Pharmaceuticals (CNTA) Debt to Equity (2022 - 2025)
Centessa Pharmaceuticals (CNTA) has disclosed Debt to Equity for 4 consecutive years, with $0.36 as the latest value for Q3 2025.
- On a quarterly basis, Debt to Equity rose 140.1% to $0.36 in Q3 2025 year-over-year; TTM through Sep 2025 was $0.36, a 140.1% increase, with the full-year FY2024 number at $0.27, down 15.33% from a year prior.
- Debt to Equity was $0.36 for Q3 2025 at Centessa Pharmaceuticals, up from $0.32 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.36 in Q3 2025 to a low of $0.15 in Q3 2024.
- A 4-year average of $0.26 and a median of $0.27 in 2024 define the central range for Debt to Equity.
- Peak YoY movement for Debt to Equity: plummeted 46.84% in 2024, then soared 140.1% in 2025.
- Centessa Pharmaceuticals' Debt to Equity stood at $0.21 in 2022, then skyrocketed by 54.33% to $0.32 in 2023, then dropped by 15.33% to $0.27 in 2024, then surged by 34.22% to $0.36 in 2025.
- Per Business Quant, the three most recent readings for CNTA's Debt to Equity are $0.36 (Q3 2025), $0.32 (Q2 2025), and $0.28 (Q1 2025).